AI pharmaceutical-development unicorn Deep Intelligent Pharma has recently completed a new financing round of US$60 mill ...

Improved Pharma, a leader in pharmaceutical research and solid-state chemistry, is pleased to announce a significant upgrade to its analytical capabilities with the installation of a fully automated ...

The collaboration intends to improve compound screening by employing CADD and AI technologies.

And there's more than one way to monetize this technology.

Opinion: Freedom-to-operate analysis must be understood as a continuous, integrated process that evolves alongside science, regulation, and commercial strategy.

Royalty Pharma plc has completed a transaction to monetize remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in cash, resulting in total proceeds of $530 million ...

Silo Pharma, Inc., a biopharmaceutical company focused on developing innovative treatments for mental health and chronic pain, announced in a recent letter to shareholders that it expects to submit an ...

MaaT Pharma secures important funding in line with one of the goals under the Health Innovation 2030 Plan, the health component of 'France 2030', led by the Health Innovation Agency dedicated to ...

Add Yahoo as a preferred source to see more of our stories on Google. LONDON, Dec 11 (Reuters) - Danish biotech Zealand Pharma said on Thursday it will accelerate development and expand its research ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408 ...

The biotech is now banking on secondary data signals as it progresses ignaseclant to late-stage trials in Charcot-Marie-Tooth ...

Lantern Pharma, Inc. (NASDAQ:LTRN) is one of the best AI penny stocks to buy right now. On January 20, the FDA granted Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-284 an Orphan Drug Designation (ODD).